Proviral DNA as a target for HIV-1 resistance analysis

Intervirology

Volumn 58, Issue 3, 2015, Pages 184-189

  Lübke, Nadine ^a   Di Cristanziano, Veronica ^a   Sierra, Saleta ^a   Knops, Elena ^a   Schülter, Eugen ^a   Jensen, Björn ^c   Oette, Mark ^b   Lengauer, Thomas ^d   Kaiser, Rolf ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b KH d Augustinerinnen   (Germany)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d MAX PLANCK INSTITUTE FOR INFORMATICS   (Germany)

Author keywords

Cellular reservoirs; Drug resistance; HIV 1 resistance testing; Low level viremia; Proviral DNA

Indexed keywords

EDETIC ACID; PROTEINASE; PROVIRAL DNA; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; VIRUS DNA; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

ANTIVIRAL RESISTANCE; ARTICLE; BLOOD ANALYSIS; BLOOD SAMPLING; CONTROLLED STUDY; DISEASE DURATION; DRUG TARGETING; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; MAJOR CLINICAL STUDY; MEDICAL INFORMATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; RNA VIRUS; VIREMIA; VIRUS LOAD; BLOOD; DRUG EFFECTS; FEMALE; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; ISOLATION AND PURIFICATION; MALE; MIDDLE AGED; MUTATION; PROVIRUS; VIROLOGY;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; MUTATION; PROVIRUSES; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; VIRAL LOAD; VIREMIA;

EID: 84936971264     PISSN: 03005526     EISSN: 14230100     Source Type: Journal    
DOI: 10.1159/000431093     Document Type: Article

References (22)

1. Vandamme AM, Camacho RJ, Ceccherini-Silberstein F, de Luca A, Palmisano L, Paraskevis D, Paredes R, Poljak M, Schmit JC, Soriano V, Walter H, Sonnerborg A;European HIV Drug Resistance Guidelines Panel: European recommendations for the clinical use of HIV drug resistance testing: 2011 update. AIDS Rev 2011;13: 77-108
2. Laprise C, de Pokomandy A, Baril JG, Dufresne S, Trottier H: Virologic failure following persistent low-level viremia in a cohort of HIV-positive patients: results from 12 years of observation. Clin Infect Dis 2013;57: 1489-1496
3. Gonzalez-Serna A, Min JE, Woods C, Chan D, Lima VD, Montaner JS, Harrigan PR, Swenson LC: Performance of HIV-1 drug resistance testing at low-level viremia and its ability to predict future virologic outcomes and viral evolution in treatment-naive individuals. Clin Infect Dis 2014;58: 1165-1173
4. Swenson LC, Min JE, Woods CK, Cai E, Li JZ, Montaner JS, Harrigan PR, Gonzalez-Serna A: HIV drug resistance detected during low-level viraemia is associated with subsequent virologic failure. AIDS 2014;28: 1125-1134
5. Li JZ, Gallien S, Do TD, Martin JN, Deeks S, Kuritzkes DR, Hatano H: Prevalence and significance of HIV-1 drug resistance mutations among patients on antiretroviral therapy with detectable low-level viremia. Antimicrob Agents Chemother 2012;56: 5998-6000
6. Siliciano JD, Kajdas J, Finzi D, Quinn TC, Chadwick K, Margolick JB, Kovacs C, Gange SJ, Siliciano RF: Long-Term follow-up studies confirm the stability of the latent reservoir for HIV-1 in resting CD4+ T cells. Nat Med 2003;9: 727-728
7. Strain MC, Gunthard HF, Havlir DV, Ignacio CC, Smith DM, Leigh-Brown AJ, Macaranas TR, Lam RY, Daly OA, Fischer M, Opravil M, Levine H, Bacheler L, Spina CA, Richman DD, Wong JK: Heterogeneous clearance rates of long-lived lymphocytes infected with HIV: intrinsic stability predicts lifelong persistence. Proc Natl Acad Sci USA 2003;100: 4819-4824
8. Lambotte O, Chaix ML, Gubler B, Nasreddine N, Wallon C, Goujard C, Rouzioux C, Taoufik Y, Delfraissy JF: The lymphocyte HIV reservoir in patients on long-Term HAART is a memory of virus evolution. AIDS 2004;18: 1147-1158
9. Turriziani O, Andreoni M, Antonelli G: Resistant viral variants in cellular reservoirs of human immunodeficiency virus infection. Clin Microbiol Infect 2010;16: 1518-1524
10. Verhofstede C, Noe A, Demecheleer E, De Cabooter N, Van Wanzeele F, Van Der Gucht B, Vogelaers D, Plum J: Drug-resistant variants that evolve during nonsuppressive therapy persist in HIV-1-infected peripheral blood mononuclear cells after long-Term highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2004;35: 473-483
11. Delgado R: Detection of resistance mutations in proviral DNA in HIV-1 infection. Enferm Infecc Microbiol Clin 2013;31(suppl 1): 35-39
12. De Castro N, Braun J, Charreau I, Pialoux G, Cotte L, Katlama C, Raffi F, Weiss L, Meynard JL, Yazdanpanah Y, Delaugerre C, Madelaine-Chambrin I, Aboulker JP, Molina JM, E.A.s. group: Switch from enfuvirtide to raltegravir in virologically suppressed multidrug-resistant HIV-1-infected patients: a randomized open-label trial. Clin Infect Dis 2009;49: 1259-1267
13. Delaugerre C, Braun J, Charreau I, Delarue S, Nere ML, de Castro N, May T, Marchou B, Simon F, Molina JM, Aboulker JP, A.E.s. group: Comparison of resistance mutation patterns in historical plasma HIV RNA genotypes with those in current proviral HIV DNA genotypes among extensively treated patients with suppressed replication. HIV Med 2012;13: 517-525
14. Palmisano L, Galluzzo CM, Giuliano M: The importance of testing genotypic resistance in proviral DNA of patients fully responding to highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2009;51: 233-234
15. Balduin M, Sierra S, Daumer MP, Rockstroh JK, Oette M, Fatkenheuer G, Kupfer B, Beerenwinkel N, Hoffmann D, Selbig J, Pfister HJ, Kaiser R: Evolution of HIV resistance during treatment interruption in experienced patients and after restarting a new therapy. J Clin Virol 2005;34: 277-287
16. Verheyen J, Litau E, Sing T, Däumer M, Balduin M, Oette M, Fätkenheuer G, Rockstroh JK, Schuldenzucker U, Hoffmann D, Pfister H, Kaiser R: Compensatory mutations at the HIV cleavage sites p7/p1 and p1/p6-gag in therapy-naive and therapy-experienced patients. Antiviral Ther 2006;11: 879-887
17. Banks L, Gholamin S, White L, Zijenah E, Katzenstein DA: Comparing Peripheral blood mononuclear cell DNA and circulating plasma viral RNA pol genotypes of subtype C HIV-1. J AIDS Clin Res 2012;3: 141-147
18. Bon I, Alessandrini F, Borderi M, Gorini R, Re MC: Analysis of HIV-1 drug-resistant variants in plasma and peripheral blood mononuclear cells from untreated individuals: implications for clinical management. New Microbiol 2007;30: 313-317
19. Bon I, Gibellini D, Borderi M, Alessandrini F, Vitone F, Schiavone P, Re MC: Genotypic resistance in plasma and peripheral blood lymphocytes in a group of naive HIV-1 patients. J Clin Virol 2007;38: 313-320
20. Ghosn J, Pellegrin I, Goujard C, Deveau C, Viard JP, Galimand J, Harzic M, Tamalet C, Meyer L, Rouzioux C, Chaix ML;French PRIMO Cohort Study Group (ANRS CO 06): HIV-1 resistant strains acquired at the time of primary infection massively fuel the cellular reservoir and persist for lengthy periods of time. AIDS 2006;20: 159-170
21. Kabamba-Mukadi B, Duquenne A, Henrivaux P, Musuamba F, Ruelle J, Yombi JC, Bodeus M, Vandercam B, Goubau P: HIV-1 proviral resistance mutations: usefulness in clinical practice. HIV Med 2010;11: 483-492
22. Parisi SG, Boldrin C, Cruciani M, Nicolini G, Cerbaro I, Manfrin V, Dal Bello F, Franchin E, Franzetti M, Rossi MC, Cattelan AM, Romano L, Zazzi M, Andreoni M, Palu G: Both human immunodeficiency virus cellular DNA sequencing and plasma RNA sequencing are useful for detection of drug resistance mutations in blood samples from antiretroviral-drug-naive patients. J Clin Microbiol 2007;45: 1783-1788